Download PDF
CC BY-NC-ND 4.0 · Diabetologie und Stoffwechsel
DOI: 10.1055/a-2305-9093
Übersicht

Kontinuierliche Glukosemessung bei Menschen mit Typ-2-Diabetes ohne intensivierte Insulintherapie: eine Standortbestimmung

Continuous glucose monitoring (CGM) in people with type 2 diabetes not on multiple daily injections (MDI): review of current evidence and potential future positioning
Jochen Seufert 
1   Klinik für Innere Medizin II, Abteilung Endokrinologie und Diabetologie, Universitätsklinikum Freiburg, Freiburg, Germany
,
Ingrid Dänschel
2   Akademische Lehrpraxis der Universitäten Leipzig u. Dresden, Allgemeinarzt-Praxis, Lunzenau, Germany
,
Stefan Gölz
3   Diabetes Schwerpunktpraxis, amedes MVZ für Diabetologie Esslingen, Esslingen, Germany
,
Nicola Haller
4   Diabetes, Diabetes & Stoffwechsel Zentrum Starnberg, Starnberg, Germany
,
Bernhard Kulzer
5   FIDAM, Diabetes-Akademie Bad Mergentheim eV, Bad Mergentheim, Germany (Ringgold ID: RIN534127)
,
Susanne Tan 
6   Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, Essen, Germany (Ringgold ID: RIN39081)
,
Oliver Schnell
7   GmbH, Sciarc, Baierbrunn, Germany
,
Tobias Wiesner
8   Stoffwechselmedizin Leipzig, MVZ, Leipzig, Germany
,
Jens Kroeger
9   Zentrum für digitale Diabetologie, Praxis, Hamburg, Germany
› Author AffiliationsDie Erstellung der Publikation wurde durch Abbott GmbH gefördert.
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Zahlreiche Studien haben den klinischen Nutzen der kontinuierlichen Glukosemessung (CGM) bei Menschen mit Typ-1-Diabetes belegt, was auch zu einer positiven Empfehlung des Gemeinsamen Bundesausschusses (GBA) für CGM-Systeme bei Menschen mit Diabetes und intensivierter Insulintherapie (ICT/Insulinpumpentherapie) geführt hat. Inzwischen liegen die Ergebnisse zahlreicher randomisierter, beobachtender und retrospektiver Studien zum Einsatz von CGM bei Menschen mit Typ-2-Diabetes und einer nicht intensivierten Insulintherapie (BOT/SIT/CT) oder einer Therapie ohne Insulin vor. In diesem Artikel wird die aktuelle Evidenz zum Einsatz von CGM bei diesen Patientengruppen zusammengefasst und diskutiert. Die Ergebnisse dieser Studien deuten darauf hin, dass CGM auch bei Menschen ohne intensivierte Insulintherapie wirksam ist, um die glykämische Kontrolle zu verbessern und mögliche Nebenwirkungen der Insulintherapie (Hypoglykämien) zu vermeiden.

Abstract

Several studies have shown the clinical advantages of continuous glucose monitoring (CGM) in individuals with type 1 diabetes. As a result, the Joint Federal Committee (GBA) has recommended CGM systems for individuals with diabetes and intensified insulin therapy (ICT)/insulin pump therapy. Numerous randomized, observational, and retrospective studies have been conducted on the use of CGM in people with type 2 diabetes and non-intensified insulin therapy (BOT/SIT/CT) or therapy without insulin. This article provides a summary and discussion of the current evidence on the use of CGM in these patient groups. The studies indicate that CGM is effective in improving glycemic control and avoiding potential side effects of insulin therapy, such as hypoglycemia, even in individuals without intensified insulin therapy.

Schlüsselwörter

CGM - Typ 2 Diabetes - kontinuierliche Glukosemessung - intensivierte Insulintherapie - Basalinsulin unterstützte orale antidiabetische Therapie

Keywords

CGM - Type 2 diabetes - Continuous glucose monitoring - multiple daily injections - Basal insulin supplemented oral antidiabetic therapy


Publication History

Received: 01 February 2024

Accepted after revision: 07 May 2024

Article published online:
21 May 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Deutsche Diabetes Gesellschaft (DDG) und diabetesDE – Deutsche Diabetes-Hilfe. Deutscher Gesundheitsbericht Diabetes. 2023
    PubMedGoogle Scholar
  • 2 KVNO. Qualitätsbericht 2021 Disease-Management-Programme in Nordrhein. 2021
    PubMedGoogle Scholar
  • 3 Mateo JF, Gil-Guillén VF, Mateo E. et al. Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. International journal of clinical practice 2006; 60: 422-428 DOI: 10.1111/j.1368-5031.2006.00799.x.
    CrossrefPubMedGoogle Scholar
  • 4 Khunti K, Nikolajsen A, Thorsted BL. et al. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes, obesity & metabolism 2016; 18: 401-409 DOI: 10.1111/dom.12626.
    CrossrefPubMedGoogle Scholar
  • 5 Seidu S, Than T, Kar D. et al. Therapeutic inertia amongst general practitioners with interest in diabetes. Primary care diabetes 2018; 12: 87-91 DOI: 10.1016/j.pcd.2017.09.001.
    CrossrefPubMedGoogle Scholar
  • 6 Paul SK, Klein K, Thorsted BL. et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular diabetology 2015; 14: 100 DOI: 10.1186/s12933-015-0260-x.
    CrossrefPubMedGoogle Scholar
  • 7 Kaewbut P, Kosachunhanun N, Phrommintikul A. et al. Time to Treatment Intensification to Reduce Diabetes-Related Complications: A Post Hoc Study. Healthcare (Basel) 2022; 10 DOI: 10.3390/healthcare10091673. (PMID: 36141285)
    CrossrefPubMedGoogle Scholar
  • 8 Cappon G, Vettoretti M, Sparacino G. et al. Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications. Diabetes Metab J 2019; 43: 383-397 DOI: 10.4093/dmj.2019.0121. (PMID: 31441246)
    CrossrefPubMedGoogle Scholar
  • 9 Kluemper JR, Smith A, Wobeter B. Diabetes: the role of continuous glucose monitoring. Drugs Context 2022; 11 DOI: 10.7573/dic.2021-9-13. (PMID: 35775072)
    CrossrefPubMedGoogle Scholar
  • 10 Rivera-Ávila DA, Esquivel-Lu AI, Salazar-Lozano CR. et al. The effects of professional continuous glucose monitoring as an adjuvant educational tool for improving glycemic control in patients with type 2 diabetes. BMC endocrine disorders 2021; 21: 79 DOI: 10.1186/s12902-021-00742-5.
    CrossrefPubMedGoogle Scholar
  • 11 Miller EM. Using Continuous Glucose Monitoring in Clinical Practice. Clinical diabetes : a publication of the American Diabetes Association 2020; 38: 429-438 DOI: 10.2337/cd20-0043. (PMID: 33384468)
    CrossrefPubMedGoogle Scholar
  • 12 Battelino T, Danne T, Bergenstal RM. et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019; 42: 1593-1603 DOI: 10.2337/dci19-0028.
    CrossrefPubMedGoogle Scholar
  • 13 van den Boom L, Auzanneau M, Woelfle J. et al. Use of Continuous Glucose Monitoring in Pump Therapy Sensor Augmented Pump or Automated Insulin Delivery in Different Age Groups (0.5 to <26 Years) With Type 1 Diabetes From 2018 to 2021: Analysis of the German/Austrian/Swiss/Luxemburg DPV Registry. J Diabetes Sci Technol 2023; DOI: 10.1177/19322968231156601. (PMID: 36840616)
    CrossrefPubMedGoogle Scholar
  • 14 Deutsche Diabetes Gesellschaft (DDG): S3-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. 2023
    PubMedGoogle Scholar
  • 15 Weitgasser R, Ciardi C, Traub J. et al. Diabetes education and counseling in adult patients with diabetes (Update 2023). Wien Klin Wochenschr 2023; 135: 137-142 DOI: 10.1007/s00508-022-02120-0.
    CrossrefPubMedGoogle Scholar
  • 16 Bundesärztekammer (BÄK) KBK, Arbeitsgemeinschaft der Wissenschaftli-, (AWMF) cMF. Nationale VersorgungsLeitlinie Typ-2-Diabetes – Langfassung. Version 3.0. 2023 DOI: 10.6101/AZQ/000503
    CrossrefGoogle Scholar
  • 17 Powers MA, Bardsley JK, Cypress M. et al. Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Care 2020; 43: 1636-1649 DOI: 10.2337/dci20-0023.
    CrossrefPubMedGoogle Scholar
  • 18 Chatterjee S, Davies MJ, Heller S. et al. Diabetes structured self-management education programmes: a narrative review and current innovations. The Lancet Diabetes & Endocrinology 2018; 6: 130-142 DOI: 10.1016/S2213-8587(17)30239-5. (PMID: 28970034)
    CrossrefPubMedGoogle Scholar
  • 19 Tamhane S, Rodriguez-Gutierrez R, Hargraves I. et al. Shared Decision-Making in Diabetes Care. Current diabetes reports 2015; 15: 112 DOI: 10.1007/s11892-015-0688-0. (PMID: 27105298)
    CrossrefPubMedGoogle Scholar
  • 20 Beck RW, Riddlesworth TD, Ruedy K. et al. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Annals of internal medicine 2017; 167: 365-374 DOI: 10.7326/m16-2855.
    CrossrefPubMedGoogle Scholar
  • 21 Yaron M, Roitman E, Aharon-Hananel G. et al. Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. Diabetes Care 2019; 42: 1178-1184 DOI: 10.2337/dc18-0166.
    CrossrefPubMedGoogle Scholar
  • 22 Kröger J, Fasching P, Hanaire H. Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders 2020; 11: 279-291 DOI: 10.1007/s13300-019-00741-9. (PMID: 31833041)
    CrossrefPubMedGoogle Scholar
  • 23 Haak T, Hanaire H, Ajjan R. et al. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. Diabetes therapy : research, treatment and education of diabetes and related disorders 2017; 8: 55-73 DOI: 10.1007/s13300-016-0223-6.
    CrossrefPubMedGoogle Scholar
  • 24 Vigersky RA, Fonda SJ, Chellappa M. et al. Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care 2012; 35: 32-38 DOI: 10.2337/dc11-1438.
    CrossrefPubMedGoogle Scholar
  • 25 Martens T, Beck RW, Bailey R. et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. Jama 2021; 325: 2262-2272 DOI: 10.1001/jama.2021.7444.
    CrossrefPubMedGoogle Scholar
  • 26 Bao S, Bailey R, Calhoun P. et al. Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal Insulin. Diabetes Technol Ther 2022; 24: 299-306 DOI: 10.1089/dia.2021.0494.
    CrossrefPubMedGoogle Scholar
  • 27 Davis G, Bailey R, Calhoun P. et al. Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE Study. Diabetes Technol Ther 2022; 24: 324-331 DOI: 10.1089/dia.2021.0489.
    CrossrefPubMedGoogle Scholar
  • 28 Aleppo G, Beck RW, Bailey R. et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care 2021; 44: 2729-2737 DOI: 10.2337/dc21-1304. (PMID: 35349654)
    CrossrefPubMedGoogle Scholar
  • 29 Yoo HJ, An HG, Park SY. et al. Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. Diabetes research and clinical practice 2008; 82: 73-79 DOI: 10.1016/j.diabres.2008.06.015. (PMID: 18701183)
    CrossrefPubMedGoogle Scholar
  • 30 Wright EE, Kerr MSD, Reyes IJ. et al. Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy. Diabetes Spectr 2021; 34: 184-189 DOI: 10.2337/ds20-0069. (PMID: 34149259)
    CrossrefPubMedGoogle Scholar
  • 31 Ajjan RA, Jackson N, Thomson SA. Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial. Diabetes & vascular disease research 2019; 16: 385-395 DOI: 10.1177/1479164119827456. (PMID: 31271312)
    CrossrefPubMedGoogle Scholar
  • 32 Lameijer A, Bakker JJ, Kao K. et al. Real-life 24-week changes in glycemic parameters among European users of flash glucose monitoring with type 1 and 2 diabetes and different levels of glycemic control. Diabetes research and clinical practice 2023; 201 DOI: 10.1016/j.diabres.2023.110735.
    CrossrefPubMedGoogle Scholar
  • 33 Grace T, Salyer J. Use of Real-Time Continuous Glucose Monitoring Improves Glycemic Control and Other Clinical Outcomes in Type 2 Diabetes Patients Treated with Less Intensive Therapy. Diabetes Technol Ther 2022; 24: 26-31 DOI: 10.1089/dia.2021.0212. (PMID: 34524013)
    CrossrefPubMedGoogle Scholar
  • 34 Elliott T, Beca S, Beharry R. et al. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study. Diabetes & vascular disease research 2021; 18 DOI: 10.1177/14791641211021374.
    CrossrefPubMedGoogle Scholar
  • 35 Carlson AL, Daniel TD, DeSantis A. et al. Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis. BMJ Open Diabetes Res Care 2022; 10 DOI: 10.1136/bmjdrc-2021-002590.
    CrossrefPubMedGoogle Scholar
  • 36 Miller E, Kerr MSD, Roberts GJ. et al. Flash CGM associated with event reduction in nonintensive diabetes therapy. The American journal of managed care 2021; 27: e372-e377 DOI: 10.37765/ajmc.2021.88780.
    CrossrefPubMedGoogle Scholar
  • 37 Guerci B, Roussel R, Levrat-Guillen F. et al. Important Decrease in Hospitalizations for Acute Diabetes Events Following FreeStyle Libre System Initiation in People with Type 2 Diabetes on Basal Insulin Therapy in France. Diabetes Technol Ther 2023; 25: 20-30 DOI: 10.1089/dia.2022.0271.
    CrossrefPubMedGoogle Scholar
  • 38 Nathanson D, Eeg-Olofsson K, Spelman T. Intermittently-scanned CGM is associated with lower HbA1c and reduced hospital admissions for adults with T2DM on insulin therapy in Sweden: a retrospective controlled study. Presented at EASD, 2 – 6 October 2023, Hamburg, Germany. 2023
    PubMedGoogle Scholar
  • 39 Porter M, Fonda S, Swigert T. et al. Real-Time Continuous Glucose Monitoring to Support Self-Care: Results from a Pilot Study of Patients With Type 2 Diabetes. J Diabetes Sci Technol 2022; 16: 578-580 DOI: 10.1177/19322968211053886.
    CrossrefPubMedGoogle Scholar
  • 40 Riveline JP, Roussel R, Vicaut E. et al. Reduced Rate of Acute Diabetes Events with Flash Glucose Monitoring Is Sustained for 2 Years After Initiation: Extended Outcomes from the RELIEF Study. Diabetes Technol Ther 2022; 24: 611-618 DOI: 10.1089/dia.2022.0085.
    CrossrefPubMedGoogle Scholar
  • 41 Roussel R, Riveline JP, Vicaut E. et al. Important Drop in Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. Diabetes Care 2021; 44: 1368-1376 DOI: 10.2337/dc20-1690. (PMID: 33879536)
    CrossrefPubMedGoogle Scholar
  • 42 Allen NA, Fain JA, Braun B. et al. Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial. Diabetes research and clinical practice 2008; 80: 371-379 DOI: 10.1016/j.diabres.2008.01.006.
    CrossrefPubMedGoogle Scholar
  • 43 Wada E, Onoue T, Kobayashi T. et al. Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care 2020; 8 DOI: 10.1136/bmjdrc-2019-001115.
    CrossrefPubMedGoogle Scholar
  • 44 Cox DJ, Banton T, Moncrief M. et al. Minimizing Glucose Excursions (GEM) With Continuous Glucose Monitoring in Type 2 Diabetes: A Randomized Clinical Trial. J Endocr Soc 2020; 4: bvaa118 DOI: 10.1210/jendso/bvaa118.
    CrossrefPubMedGoogle Scholar
  • 45 Aronson R, Brown RE, Chu L. et al. IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial. Diabetes, Obesity and Metabolism 2023; 25: 1024-1031 DOI: 10.1111/dom.14949.
    CrossrefPubMedGoogle Scholar
  • 46 Polonsky WH, Soriano EC, Fortmann AL. The Role of Retrospective Data Review in the Personal Use of Real-Time Continuous Glucose Monitoring: Perceived Impact on Quality of Life and Health Outcomes. Diabetes Technol Ther 2022; 24: 492-501 DOI: 10.1089/dia.2021.0526. (PMID: 35255224)
    CrossrefPubMedGoogle Scholar
  • 47 Dowd R, Jepson LH, Green CR. et al. Glycemic Outcomes and Feature Set Engagement Among Real-Time Continuous Glucose Monitoring Users With Type 1 or Non-Insulin-Treated Type 2 Diabetes: Retrospective Analysis of Real-World Data. JMIR Diabetes 2023; 8: e43991 DOI: 10.2196/43991. (PMID: 36602920)
    CrossrefPubMedGoogle Scholar
  • 48 Simonson GD, Bergenstal RM, Johnson ML. et al. Effect of Professional CGM (pCGM) on Glucose Management in Type 2 Diabetes Patients in Primary Care. J Diabetes Sci Technol 2021; 15: 539-545 DOI: 10.1177/1932296821998724. (PMID: 33719598)
    CrossrefPubMedGoogle Scholar
  • 49 Jackson MA, Ahmann A, Shah VN. Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring. Diabetes Technol Ther 2021; 23: S27-s34 DOI: 10.1089/dia.2021.0007. (PMID: 33534631)
    CrossrefPubMedGoogle Scholar
  • 50 Vallis M, Ryan H, Berard L. et al. How Continuous Glucose Monitoring Can Motivate Self-management: Can Motivation Follow Behaviour?. Canadian journal of diabetes 2023; 47: 435-444 DOI: 10.1016/j.jcjd.2023.04.001. (PMID: 37044242)
    CrossrefPubMedGoogle Scholar
  • 51 Gilbert TR, Noar A, Blalock O. et al. Change in Hemoglobin A1c and Quality of Life with Real-Time Continuous Glucose Monitoring Use by People with Insulin-Treated Diabetes in the Landmark Study. Diabetes Technol Ther 2021; 23: S35-s39 DOI: 10.1089/dia.2020.0666.
    CrossrefPubMedGoogle Scholar
  • 52 Bergenstal RM, Layne JEL Zisser H. et al. Dixon. Remote Application and Use of Real-Time Continuous Glucose Monitoring by Adults with Type 2 Diabetes in a Virtual Diabetes Clinic. Diabetes Technology & Therapeutics 2021; 23: 128-132 DOI: 10.1089/dia.2020.0396.
    CrossrefPubMedGoogle Scholar
  • 53 Polonsky WH, Layne JE, Parkin CG. et al. Impact of Participation in a Virtual Diabetes Clinic on Diabetes-Related Distress in Individuals With Type 2 Diabetes. Clinical diabetes : a publication of the American Diabetes Association 2020; 38: 357-362 DOI: 10.2337/cd19-0105.
    CrossrefPubMedGoogle Scholar
  • 54 Bahrmann A, Wörz E, Specht-Leible N. et al. Diabetes care and incidence of severe hypoglycemia in nursing home facilities and nursing services: The Heidelberg Diabetes Study. Z Gerontol Geriatr 2015; 48: 246-254 DOI: 10.1007/s00391-014-0626-9. (PMID: 24740530)
    CrossrefPubMedGoogle Scholar
  • 55 Mattishent K, Richardson K, Dhatariya K. et al. The effects of hypoglycaemia and dementia on cardiovascular events, falls and fractures and all-cause mortality in older individuals: A retrospective cohort study. Diabetes, obesity & metabolism 2019; 21: 2076-2085 DOI: 10.1111/dom.13769. (PMID: 31069922)
    CrossrefPubMedGoogle Scholar
  • 56 Deutsche Diabetes Gesellschaft (DDG): S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. 2018
    PubMedGoogle Scholar
  • 57 Kosjerina V, Carstensen B, Jørgensen ME. et al. Discontinuation of diabetes medication in the 10 years before death in Denmark: a register-based study. The Lancet Healthy Longevity 2021; 2: e561-e570 DOI: 10.1016/S2666-7568(21)00170-7.
    CrossrefPubMedGoogle Scholar
  • 58 Ahlqvist E, Storm P, Käräjämäki A. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. The lancet Diabetes & endocrinology 2018; 6: 361-369 DOI: 10.1016/s2213-8587(18)30051-2.
    CrossrefPubMedGoogle Scholar
  • 59 Hall H, Perelman D, Breschi A. et al. Glucotypes reveal new patterns of glucose dysregulation. PLoS Biol 2018; 16: e2005143 DOI: 10.1371/journal.pbio.2005143. (PMID: 30040822)
    CrossrefPubMedGoogle Scholar
  • 60 Bergenstal RM, Mullen DM, Strock E. et al. Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes. Journal of diabetes and its complications 2022; 36: 108106 DOI: 10.1016/j.jdiacomp.2021.108106. (PMID: 35131155)
    CrossrefPubMedGoogle Scholar
  • 61 Khunti K, Gomes MB, Pocock S. et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes, obesity & metabolism 2018; 20: 427-437 DOI: 10.1111/dom.13088.
    CrossrefPubMedGoogle Scholar
  • 62 Reach G, Pechtner V, Gentilella R. et al. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes & metabolism 2017; 43: 501-511 DOI: 10.1016/j.diabet.2017.06.003.
    CrossrefPubMedGoogle Scholar
  • 63 Giugliano D, Maiorino MI, Bellastella G. et al. Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes. Journal of endocrinological investigation 2019; 42: 495-503 DOI: 10.1007/s40618-018-0951-8. (PMID: 30291589)
    CrossrefPubMedGoogle Scholar
  • 64 Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes, obesity & metabolism 2018; 20: 488-496 DOI: 10.1111/dom.13132. (PMID: 29053215)
    CrossrefPubMedGoogle Scholar
  • 65 Polonsky WH, Fisher L, Guzman S. et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005; 28: 2543-2545 DOI: 10.2337/diacare.28.10.2543.
    CrossrefPubMedGoogle Scholar
  • 66 Peyrot M, Barnett AH, Meneghini LF. et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetic medicine : a journal of the British Diabetic Association 2012; 29: 682-689 DOI: 10.1111/j.1464-5491.2012.03605.x. (PMID: 22313123)
    CrossrefPubMedGoogle Scholar
  • 67 Gerstein HC, Miller ME, Genuth S. et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. The New England journal of medicine 2011; 364: 818-828 DOI: 10.1056/NEJMoa1006524. (PMID: 21366473)
    CrossrefPubMedGoogle Scholar